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Background: Adequate sleep is essential for health. Both, short and long sleep durations are asso-
ciated to worse quality of  life and poor health outcomes. Portugal represents a specific population 
model, since according to European statistics it has high rates of  chronic diseases like depression, 
hypertension, diabetes and stroke; and low quality of  life as well as low index of  physical activity, 
while in parallel it has some other good health indicators such as: low age-standardized mortality 
for both genders, nutrition in terms of  energy and fruit consumption, smoking and alcohol, obesity 
and overweight prevalence. The aim of  this study was to characterize health and chronic diseases, 
lifestyles and quality of  life in subjects with short and long sleep duration. Methods: A population-
based cross-sectional evaluation of  the third wave of  follow-up of  the EpiDoC Cohort was carried 
between 2015-2016. A sample of  5,436 adults ≥18 years, representative of  the national population, 
self-reported their daily total sleep time. Associations between short sleep duration (SSD ≤5h), long 
sleep duration (LSD≥9h) and independent variables were determined. Results: The prevalence for 
SSD was high (20.7%) and the LSD (5.9%) was low. Being older, with lower education, retired and 
unemployed were associated to SSD and LSD (p<0.01). Being obese was associated to SSD as well 
as hypertension, gastrointestinal disease and hypercholesterolemia (p<0.01). SSD and LSD, were 
associated with diabetes (p<0.01 and p=0.03) and depression (p<0.01 and p=0.02) respectively. Car-
diovascular disease (p<0.01) was associated to LSD. Multimorbidity (p<0.01) was associated to SSD. 
Worse quality of  life and bad physical function were associated to SSD and LSD, as well as being 
hospitalized in the previous 12 months (p<0.01). Conclusions: Socio-demographic, physical activ-
ity and chronic diseases were associated to reduction and extension of  sleep duration. There was no 
association between rheumatic diseases and cancer with sleep duration, as found in other studies. 
This study emphasizes the burden of  self-reported SSD for Portugal, its consequences to health 
and the need to increase sleep awareness campaigns enhancing the importance of  sleep in health. 
Furthermore, it emphasizes that chronic diseases risks are dependent on multiple parameters which 
varying in different countries or regions, imply the need of  regional studies and interventions.
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Sleep is an active process providing daily restoration due 
to production of  the fundamental anabolic hormones, involved 
in cellular growth and regeneration such as: growth hormone, 
testosterone, prolactin, etc.1. Sleep represents an essential ele-
ment for health and well-being, including cognitive perfor-
mance, physiological processes, emotion regulation, physical 
development, and quality of  life2.
Optimal sleep duration is a question often posed to sleep 
specialists, although it varies significantly between individuals, 
age, gender2, and world region3. The value established for short 
sleep duration in adults has been sometimes controversial, but 
a National study in the United States of  America (USA)4 and 
other one in Brazil5 point out to ≤6 hours, or by the recent 
values established by the National Sleep Foundation ≤5 hours2. 
The value established for long sleep is much more consensual, 
≥9 hours2,6. Insufficient sleep is well recognized and declared as 
a “public health problem” by the Center of  Disease and Control 
in the United States, and has high economic impact on a coun-
try’s economy7. It has been demonstrated unequivocally that du-
ration, timing, and quality of  sleep critically affect physical and 
mental health, performance and safety8.
Short and long sleep duration are positively associated 
with chronic diseases like obesity, type 2 diabetes, hypertension, 
and cardiovascular disease among adults6,9 Several studies sug-
gest that short sleep duration is associated with poor general 
health10,11. This association is less evident for the relationship 
between longer sleep duration and adverse health status: only 
a few studies associate poorer general health or increased risk/
presence of  disease with ≥9 hours of  sleep12. Evidence be-
tween association to long sleep and poor health was only clear 
for mortality risk, showing a U-shaped relationship12. In a re-
cent longitudinal study from a Swedish cohort this U-shaped 
relationship was also observed with mortality and age: among 
younger individuals (≤65 years) there was an increased mortality 
rate and a subsequent decrease in life expectancy. In older indi-
viduals (≥65 years) this association was not detected13.
Culture, socioeconomic status and environment have 
an important influence on sleep duration. In a large twin study, 
authors determined the relative importance of  environmental 
contributions associated to sleep duration and body mass index 
(BMI), accounting for genetics and shared environment. They 
support the environmental hypothesis that voluntary changes 
to usual sleep duration influence BMI independently of  familial 
factors14
Eurostat data indicate that Portugal (PT) is the EU-28 
country with higher rates of  chronic depression and diabetes, 
2nd rank in reported prescribed medicines, and in 7th rank for hy-
pertension15; but the relationship to these high prevalent chronic 
conditions, consumptions and sleep, were not yet evaluated.
There are two possible conditions for having short sleep 
duration: insomnia or sleep deprivation. Since the prevalence 
for insomnia in PT is approximately the same as in other coun-
tries16,17 the other option might be sleep deprivation.
The aim of  this population-based study was to charac-
terize health and chronic diseases, lifestyles and quality of  life 
in subjects with disturbances in short and long sleep duration.
METHODS
Study population
This study is a cross-sectional evaluation of  the third 
wave of  follow-up of  the EpiDoC Cohort (i.e., the EpiDoC3 
study). EpiDoc3 participants who answer the “hours of  sleep 
per day” question, were included in the current analysis. Epi-
DoC cohort was designed to study health determinants and out-
comes, chronic non-communicable diseases and their impact in 
health resources consumption. The EpiDoC cohort enrolled 
10,661 adults living in PT (mainland and the archipelagos of  
Azores and Madeira). EpiDoC sample size calculation was per-
formed to capture health related conditions whose prevalence 
were of  0.5% as described elsewhere18,19. The study included 
non-institutionalized adults (≥18 years old) living in private 
homes in the Portuguese mainland and archipelagos (Madeira 
and Azores). The study sample was stratified by administra-
tive territorial units [(NUTSII) (Norte, Centro, Lisboa & Vale 
do Tejo, Alentejo, Algarve, Açores archipelago (Azores) and 
Madeira archipelago (Madeira)], and the size of  the popula-
tion within each locality (<2,000; 2,000-9,999; 10,000-19,999; 
20,000-99,999; and ≥100,000 inhabitants, respectively). Detailed 
methodology has been published18. EpiDoC3 study included 
5,653 adult participants (Figure 1), of  whom 5,436 reported 
their daily total sleep time. Data collection was performed from 
September 2015 to July 2016 by a trained research assistant team 
who randomly called all individuals by telephone.
EpiDoC cohort measurements
Sociodemographic and socioeconomic characteristics
Information regarding sociodemographic factors (sex, 
age, ethnicity, years of  education, marital status, household 
composition, Nomenclature of  Territorial Units for Statistics 
[NUTS]II region), as well as socioeconomic variables (employ-
ment status), were collected in the EpiDoC1 study. During the 
EpiDoC3 interview, subjects were asked whether any of  these 
characteristics had changed. The variable age was also catego-
rized as <65 years and ≥65 years of  age, since there are impor-
tant changes in sleep duration and architecture during the life 
span and after retirement2,13.
Lifestyle characteristics
The daily total sleep time was assessed by the ques-
tion “On average, how many hours do you sleep per day?” and the 
sleep categories were established as short sleep duration (SSD) 
(≤5h), normal sleep duration (NSD) (>5h and <9h) and long 
sleep duration (LSD) (≥9h), according to the National Sleep 
Foundation2.
Self-reported height and weight were collected. Based 
on these data, body mass index (BMI; weight/height2 in kg/m2) 
was calculated and categorized according to the World Health 
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Figure 1. Flowchart of  the study.
Organization (WHO) classification system20 EpiDoC3 study 
included several questions concerning lifestyle habits, such as 
frequency of  alcohol intake (never, daily, occasionally), smok-
ing habits (current smoker, past smoker and never smoked), 
physical activity and dietary habits. Physical activity level was 
classified according to self-reported weekly frequency of  physi-
cal activity and categorized by active or inactive. For the time 
watching TV a categorical variable was used (<5 hours/day or 
≥5 hours/day). For the dietary intake, a proxy of  healthy diet 
was assessed by calculating  the adherence to the Mediterranean 
diet through the PREDIMED score21.
Health characteristics and healthcare consumption and 
costs
In EpiDoC3 study, individuals were asked whether they 
had been previously diagnosed with the following chronic dis-
eases: hypercholesterolemia, hypertension, rheumatic disease, 
allergy, gastrointestinal disease, cardiac disease, diabetes, pul-
monary disease, cancer, or neurologic disease, depression and 
anxiety. Multimorbidity was defined as the coexistence of  two 
or more of  these self-reported chronic diseases22. Health-related 
quality of  life was assessed using the European Quality of  Life 
questionnaire with five dimensions and three levels (EQ-5D-
3L)23,24, for which a higher score corresponds to a higher quality 
of  life. Physical function was evaluated using the Health Assess-
ment Questionnaire (HAQ; ranging from 0 to 3, with higher 
scores representing worse functional ability)25.
We used Portuguese validated versions of  the assess-
ment scales. Number of  hospitalizations were also assessed.
Statistical analysis
To verify the representativeness of  the sample according 
to the Portuguese population (mainland and islands), we first 
compared the participants and non-participants of  EpiDoC3 
study with respect to their sociodemographic, socioeconomic, 
and health status characteristics. Based on this comparison, 
we adjusted the weights according to stratification by NUT-
SII region, sex, and age group. Extrapolation weights were 
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computed and used in the subsequent statistical analysis. These 
were obtained by calibrating the extrapolation weights originally 
designed for the EpiDoC1 study sample. 
Baseline characteristics of  the study cohort were de-
scribed according to the three categories of  reported sleep du-
ration: SSD (≤5h), NSD (>5h and <9h) and LSD (≥9h).
Absolute frequencies and weighted proportions were 
used to summarize categorical variables. Continuous variables 
were described by weighted mean values and standard devia-
tions. Differences in baseline variables across categories of  re-
ported sleep duration were statistically assessed using the Stu-
dent t-test for continuous variables and the Chi-square test for 
categorical variables. For the post-hoc comparisons between 
groups the Sheffé’s method was used. Logistic regression was 
used to computed odds ratio (OR) and respective 95% confi-
dence intervals (95% CI) to quantify the association between ex-
planatory variable and sleep duration SSD and LSD. Crude and 
gender, age (<65 years vs ≥65 years), NUTSII and educational 
level adjusted OR were estimated. All analyses were weighted 
and performed using STATA IC v.12 (StataCorp. 2011. Stata 
Statistical Software: Release 12. College Station, TX: StataCorp 
LP).
Ethical issues and personal protection
Details of  ethical issues of  the EpiDoC1 (EpiReumaPt) 
study were described elsewhere18,19,26. The study was reviewed 
and approved by the National Committee for Data Protection 
(Comissão Nacional de Proteção de Dados) and by NOVA Medical 
School Ethics Committee. Informed consent was obtained from 
all individual participants included in all phases of  the study.
EpiDoC3 was also approved by the National Commit-
tee for Data Protection (in accordance with the Portuguese law 
number 67/98, October 26th, regarding protection of  personal 
data) and by the same Ethics Committee as EpiDoC1. The 
study was conducted in accordance with the applicable laws 
and regulations including, but not limited to, the Guidelines for 
Good Clinical Practice and the ethical principles stated in the 
Declaration of  Helsinki27. Participants’ confidentiality was safe-
guarded by the absence of  identifiers in the database (only a 
unique identification code was used for each participant). The 
name and contact information for each subject were stored 
separately from the study data transmitted to the coordinating 
center (based at the headquarters of  the Portuguese Society of  
Rheumatology). All data were kept anonymously and secured by 
authorized EpiDoC staff.
RESULTS
In total, 5,436 participants reported their daily total sleep 
time. Participants’ mean age was 56.7±16.4 years old and 3,473 
(52.7%) were females. For the adult Portuguese population, self-
reported SSD prevalence was 20.7%, and LSD prevalence was 
5.9%. For the Portuguese country distribution, the region with a 
higher prevalence value of  reported SSD was the Algarve (south 
of  PT) (26.5%), while the Atlantic Islands of  Azores have the 
lowest value (16.4%), and the higher prevalence of  LSD (10.2%). 
Lisbon was the region with a higher prevalence value of  normal 
sleep duration (75.8%). Participants with reported SSD (≤5h) 
were older (≥65), most frequently women, with lower education 
level, widowed and retired, unemployed or in a temporary work. 
The same pattern was found for reported LSD (≥9) (Table 1).
There is a higher percentage of  overweight subjects in 
the SSD group, as well as people that drink alcohol on a daily 
basis and the ones that never smoke. The percentage of  inac-
tive and active individuals was similar for both sleep duration 
groups, except for the LSD with a higher prevalence in the inac-
tive group. Subjects that adhere to a Mediterranean diet were the 
ones with higher percentage of  reported normal sleep (78.2%), 
although a very high percentage of  individuals did not have a 
high adherence to the Mediterranean diet (88.1%) according to 
the PREDIMED score.
The self-reported non-communicable chronic diseases 
with a prevalence value above 30% for the reported SSD group 
were: hypertension (34.6%), diabetes (39.4%), hypercholester-
olemia (32.7%), pulmonary disease (31.0%), cardiac disease 
(33.9%), gastrointestinal disease (33.7%) and neoplasm disease 
(31.2%). For the reported LSD group, the self-reported non-
communicable chronic diseases with higher prevalence’s were: 
diabetes (9.4%), pulmonary disease (9.3%), cardiac disease 
(11.8%) and neoplasm disease (9.0%). The pathology with lower 
prevalence for reported normal sleep duration was diabetes with 
51.2%. The percentage of  individuals with anxiety was higher 
in the SSD group (26.1%) and the percentage of  individuals 
with depression and anxiety was the same in the reported LSD 
group, 5.8%. For the SSD the percentage of  individuals with 
depression was 31.4%.
The percentage of  multimorbidity was high in the 
groups of  SSD and LSD with 36.3% and 7.6% respectively 
although it was only statistically significant associated to SSD, 
when adjusted to age, gender, educational level and regions. 
For physical function, the group with SSD presented the low-
est physical function (0.61±0.74), comparing to the LSD group. 
LSD group presented a low physical function when compared 
to the normal group. The number of  hospitalizations in the pre-
vious 12 months was higher in the SSD group (28.1%). Asked 
about medication, 234 (2.8%) individuals reported specifically 
taking medication for sleep, and 40.3% of  those belong to the 
SSD group.
SSD was weakly associated “to drinking alcohol occasionally”, 
never smoke and to have a high adherence to Mediterranean 
diet (Table 2).
Lifestyle variables weakly associated to reported LSD 
(≥9 hours/day) were “to drink alcohol daily and occasionally” 
(OR=0.56; 95%CI:0.39-0.81); and to watch TV ≥5 hours/day 
(OR=1.92; 95%CI:1.15-3.21). In the adjusted model, the only 
lifestyle variable associated to LSD (≥9 hours/day) was daily al-
cohol consumption (OR=0.62; 95%CI:0.42-0.90) (Table 2). For 
the remaining lifestyles studied no association was obtained for 
sleep duration.
Table 3 displays data on health conditions and health 
resources consumptions crude and adjusted for age, gender, 
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Table 1. Baseline characteristics by categories of  short (≤5 h/day) and long (≥9h/day) sleep duration, having as reference group the normal sleep duration 
(6-8 h/day) for the Portuguese population.
Post-hoc comparisons (Sheffé’s method)
Short*Normal Short*Long Normal*Long
Characteristic
Short sleep duration 
(≤ 5 h/day)
Normal sleep duration 
(6-8 h/day)
Long sleep duration 
(≥9h/day) p-value
a p-value p-value p-value
N (%) 1337 (20.7) 3693 (73.4) 406 (5.9)
Sex, N (%)
Male 411 (19.4) 1401 (75.0) 151 (5.7) 0.2514 ___ ___ ___
Female 926 (22.0) 2292 (71.9) 255 (6.1) ___ ___ ___
Age, mean ± (SD) 58.5 (17.2) 46.1 (16.5) 56.3 (22.9) <0.0001 <0.0001 ___ <0.0001
Age groups, N (%)
< 65 years 717 (15.8) 2704 (79.7) 199 (4.5) <0.0001 <0.0001 <0.0001 <0.001
≥ 65 years 620 (36.4) 989 (53.2) 207 (10.4) <0.0001 <0.0001 <0.0001
NUTS II region, N (%)
North 404 (20.3) 1080 (73.7) 120 (6.0) 0.1802 ___ ___ ___
Centre 260 (20.9) 688 (72.1) 91 (7.0) ___ ___ ___
Lisbon 244 (20.3) 798 (75.8) 53 (3.9) ___ ___ ___
Alentejo 75 (21.8) 208 (70.7) 28 (7.5) ___ ___ ___
Algarve 57 (26.5) 109 (66.0) 8 (7.5) ___ ___ ___
Azores 130 (16.4) 430 (73.4) 76 (10.2) ___ ___ ___
Madeira 167 (21.5) 380 (74.2) 30 (4.3) ___ ___ ___
BMI, mean ± (SD) 27.0 (4.7) 25.5 (4.2) 26.2 (5.5) <0.0001 <0.0001 ___ <0.0001
Education level, N (%)
> 12 years 142 (11.0) 870 (86.7) 30 (2.4) <0.0001 <0.0001 <0.0001 <0.0001
10-12 years 164 (13.9) 801 (80.7) 66 (5.4) <0.0001 <0.001 ___
5-9 years 263 (20.1) 767 (75.1) 64 (4.8) ___ ___ <0.05
0-4 years 756 (34.7) 1244 (55.7) 239 (9.7) <0.0001 <0.0001 <0.0001
Marital status, N (%)
Single 134 (9.6) 713 (85.1) 57 (5.3) <0.0001 <0.0001 <0.001 ___
Married 833 (23.9) 2267 (70.3) 235 (5.7) ___ ___ ___
Divorced 86 (26.9) 266 (66.7) 28 (6.4) ___ ___ ___
Widowed 250 (39.5) 319 (51.0) 72 (9.5) <0.0001 <0.0001 <0.001
Consensual union 34 (15.2) 126 (80.5) 12 (4.3) ___ ___ ___










95 (7.3) ___ ___ ___
Alcohol intake, N (%)
Daily 371 (23.9) 1058 (70.8) 113 (5.3) <0.0001 <0.0001 <0.001 <0.01
Occasionally 389 (16.0) 1487 (79.0) 115 (5.0) ___ ___ ___
Never 573 (23.7) 1142 (68.6) 176 (7.7) <0.0001 <0.001 <0.01
Smoking habits, N (%)
Current smoker 157 (14.0) 654 (81.0) 58 (5.0) 0.0003 <0.05 ___ ___
Past smoker 276 (21.5) 764 (72.1) 93 (6.4) ___ ___ ___
222Reis, et al.
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Never 901 (23.0) 2272 (70.9) 255 (6.1) <0.001 <0.01 ___
Physical activity, N (%)
Inactive 803 (21.3) 2035 (72.4) 261 (6.4) 0.3879 ___ ___ ___
Active 534 (20.1) 1658 (74.6) 145 (5.3) ___ ___ ___
Time watching TV, N (%) 
< 5 hours/per day 1170 (20.4) 3366 (74.0) 333 (5.5) 0.0961 ___ ___ ___
≥ 5 hours/per day 163 (23.6) 318 (66.8) 71 (9.6) ___ ___ ___
Adherence to 
Mediterranean diet, N (%) 
High adherence to MD 
(PREDIMED ≥ 10) 122 (16.4) 439 (78.2) 40 (5.3) 0.0672 ___ ___ ___
Low adherence to MD 




Hypertension 585 (34.6) 1053 (58.5) 151 (6.9) <0.0001 <0.0001 <0.0001 <0.05
Diabetes 224 (39.4) 354 (51.2) 66 (9.4) <0.0001 <0.0001 <0.001 <0.01
Hypercholesterolemia 565 (32.7) 1054 (60.2) 141 (7.2) <0.0001 <0.0001 <0.001 ___
Pulmonary disease 65 (31.0) 113 (59.7) 20 (9.3) 0.0010 <0.05 <0.05 ___
Cardiac disease 218 (33.9) 359 (54.4) 90 (11.8) <0.0001 <0.001 <0.0001 <0.0001
Gastrointestinal disease 190 (33.7) 287 (58.8) 47 (7.5) <0.0001 <0.0001 <0.001 ___
Neurologic disease 54 (18.3) 129 (74.9) 19 (6.8) 0.7257 ___ ___ ___
Allergy 135 (18.5) 371 (76.7) 28 (4.8) 0.4468 ___ ___ ___
Neoplasm disease 93 (31.2) 181 (59.8) 31 (9.0) 0.0045 <0.05 ___ ___
Rheumatic disease 154 (25.9) 296 (65.8) 43 (8.4) 0.0497 <0.01 <0.05 ___
Depression 141 (31.4) 265 (59.1) 37 (5.8) <0.0001 <0.01 <0.05 ___
Anxiety 79 (26.1) 159 (65.7) 23 (5.8) 0.1338 ___ ___ ___
Multimorbidity, N (%)
Yes 532 (36.3) 899 (56.1) 142 (7.6) <0.0001 <0.0001 <0.0001 <0.01
No 698 (16.0) 2585 (79.2) 207 (4.8) <0.0001 <0.001 <0.05
Hospitalized in previous 
12 months, N (%)
212 (28.1)
425 (61.9)
70 (10.0) <0.0001 <0.01 <0.05 <0.05
Physical function, mean 
+ (SD)
HAQ score (0-3) 0.6 (0.7) 0.3 (0.5) 0.5 (0.7) <0.0001 <0.0001 <0.01 <0.0001
Quality of  life, mean + 
(SD)
EQ-5D-3L score 0.7 (0.3) 0.8 (0.2) 0.7 (0.3) <0.0001 <0.0001 ___ <0.0001
Drugs for sleep 
(self- reported) , N (%)
Yes 93 (40.3) 122 (53.1) 19 (6.6) <0.0001 <0.0001 <0.01 ___
No 1244 (20.2) 3571 (74.0) 387 (5.9) ___ ___ ___
aAnova and Pearson Qui2 tests.
NUTSII regions and educational level. To be overweight or 
obese (OR=1.57; 95%CI:1.24-1.99) was statistically significant 
associated to reported short sleep duration. Diabetes and de-
pression presented higher prevalence values for SSD and LSD 
presenting an increased risk for both conditions. Hypercholes-
terolemia had an increased risk for SSD (OR=1.47; 95%CI:1.16-
1.86). Gastrointestinal disease presented also an increased risk 
for the same group (OR=1.68; 95%CI:1.19-2.37). Cardiac dis-
ease was associated to LSD (OR=2.01; 95%CI:1.45-2.78). 
For the remaining chronic diseases studied like rheumatic, 
neoplastic and pulmonary diseases there was an association to sleep 
duration only in the univariate analysis, this association was not 
found for the adjusted analysis. Allergic and neurologic diseases had 
no association to SSD and LSD in this population (Table 3).
Continuation Table 1.
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Table 2. Lifestyles factors associated with short and long sleep durations for the Portuguese population.
Crude Multivariable adjusteda
Sleep duration 
(≤ 5 h/day vs 6-8h/day)
Sleep duration 
(≥ 9h/day vs 6-8 h/day)
Sleep duration 
(≤ 5 h/day vs 6-8h/day)
Sleep duration 
(≥ 9h/day vs 6-8 h/day)
OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI
Alcohol intake
Daily 0.98 0.73-1.31 0.67 0.48-0.93 0.99 0.75-1.32 0.62 0.42-0.90
Occasionally 0.59 0.45-0.77 0.56 0.39-0.81 0.87 0.67-1.13 0.80 0.56-1.15
Smoking habits
Past smoker 0.92 0.70-1.21 1.03 0.75-1.42 0.99 0.74-1.33 1.20 0.81-1.77
Never 0.53 0.39-0.72 0.72 0.46-1.11 0.75 0.53-1.07 1.05 0.65-1.68
Physical activity
Active 0.91 0.73-1.15 0.82 0.61-1.10 1.11 0.89-1.39 1.02 0.76-1.37
Time watching TV  
≥ 5 hours/per day 1.28 0.77-2.13 1.92 1.15-3.21 0.78 0.52-1.17 1.25 0.80-1.96
Mediterranean diet
High adherence to MD (PREDIMED ≥ 10) 0.71 0.53-0.97 0.83 0.53-1.30 0.79 0.56-1.10 0.85 0.54-1.33
aOdds ratios from logistic regression model adjusted for age, sex, NUTS II regions and educational level.
Table 3. Health and health resources consumption factors associated with short and long sleep durations for the Portuguese population.
Crude Multivariable adjusteda
Sleep duration 
(≤ 5 h/day vs. 6-8h/day)
Sleep duration 
(≥ 9h/day vs. 6-8 h/day)
Sleep duration 
(≤ 5 h/day vs. 6-8h/day)
Sleep duration 
(≥ 9h/day vs. 6-8 h/day)
OR 95 % CI OR 95 % CI OR 95 % CI OR   95 % CI
Drugs for sleep (self- reported)
Yes 0.36 0.25-0.52 0.64 0.36-1.16 0.62 0.42-0.91 1.12 0.62-2.03
BMI
Overweight and obese  
(≥ 25 kg/m2) 2.01 1.59-2.54 1.29 0.95-1.74 1.57 1.24-1.99 1.00 0.72-1.38
Non-communicable chronic diseases (self-reported)
Hypertension 2.86 2.27-3.60 1.75 1.32-2.33 1.43 1.11-1.83 0.98 0.74-1.31
Diabetes 3.10 2.20-4.36 2.58 1.82-3.66 1.60 1.15-2.24 1.48 1.04-2.10
Hypercholesterolemia 2.53 2.01-3.18 1.77 1.33-2.36 1.47 1.16-1.86 1.11 0.82-1.49
Pulmonary disease 1.88 1.26-2.80 2.00 1.14-3.52 1.13 0.77-1.67 1.22 0.68-2.18
Cardiac disease 2.45 1.74-3.46 3.15 2.27-4.37 1.42 0.99-2.03 2.01 1.45-2.78
Gastrointestinal disease 2.22 1.57-3.15 1.69 1.04-2.74 1.68 1.19-2.37 1.40 0.88-2.24
Neurologic disease 0.86 0.56-1.33 1.14 0.55-2.36 0.75 0.45-1.25 1.04 0.49-2.19
Allergy 0.84 0.59-1.20 0.77 0.43-1.38 1.16 0.84-1.62 0.99 0.53-1.83
Neoplastic disease 1.91 1.17-3.12 1.95 1.22-3.12 1.15 0.71-1.87 1.29 0.80-2.09
Rheumatic disease 1.43 0.95-2.14 1.65 1.07-2.54 1.08 0.75-1.55 1.36 0.88-2.09
Depression 1.98 1.47-2.67 2.16 1.36-3.42 1.56 1.16-2.11 1.77 1.08-2.88
Anxiety 1.43 1.00-2.06 1.60 0.75-3.39 1.29 0.86-1.94 1.39 0.60-3.23
Multimorbidity
Yes 3.20 2.51-4.08 2.24 1.67-3.01 1.56 1.20-2.02 1.28 0.94-1.76
Physical function
HAQ score 2.84 2.37-3.41 2.32 1.87-2.88 1.75 1.42-2.15 1.58 1.22-2.05
Quality of  life
EQ-5D-3L score 0.20 0.14-0.28 0.53 0.35-0.79 0.15 0.10-0.23 0.31 0.20-0.50
Hospitalised in previous 12 months 1.71 1.33-2.20 2.23 1.56-3.19 1.36 1.05-1.76 1.83 1.25-2.70
aOdds ratios from logistic regression model adjusted for age, sex, NUTS II regions and educational level.
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Multimorbidity presented only an increased risk for SSD 
in the adjusted model (OR=1.56; 95%CI:1.20-2.02). The rela-
tionship between sleep duration and mean number of  comor-
bidities for the Portuguese population is showed in Figure 2.
Physical function and quality of  life were reduced for 
both groups (SSD: OR=1.75; 95%CI:1.42-2.15; LSD: OR=1.58; 
95%CI:1.22-2.05) and (SSD: OR=0.15; 95%CI:0.10-0.23; LSD: 
OR=0.31; 95%CI: 0.20-0.50) respectively, indicating that poor sleep 
is related to poor quality of  life and poor physical functioning. As 
a proxy for the costs for the National Health Care System we used 
the number of  hospitalizations in the previous twelve months; both 
groups presented an increased risk of  being hospitalized in the pre-
vious twelve months to the inquire (SSD: OR=1.36; 95%CI:1.05-
1.76; LSD: OR=1.83; 95%CI:1.25-2.70) (Table 3).
Splitting the sample in two groups, bellow and above 
65 years, some differences were found. Marital status was 
(p<0.0001) only associated to sleep duration in the age group 
bellow 65 years, with a high percentage of  divorced people in 
the SSD group. Also, a higher percentage of  retired/unem-
ployed or with a temporary work was associated to SSD in this 
age group (p=0.0198); and the alcohol intake (p=0.0157) was 
also higher for SSD. More statistically significant associations in 
this age group were found in non-communicable chronic diseas-
es: diabetes (p<0.0001), hypercholesterolemia (p<0.0001), gas-
trointestinal disease (p=0.0001), rheumatic diseases (p=0.0191), 
depression (p<0.0001) and anxiety (p=0.0477). A higher number 
of  hospitalizations (p=0.0007) and a higher use of  drugs for 
sleep was associated to SSD for the age group < 65 years. The 
only variable associated to sleep duration for the age group ≥ 
65 was the adherence to Mediterranean diet, where participants 
with a lower adherence were more present in the SSD group 
(Table 4).
For the <65 years group the lifestyle factors with 
a predictive value for SSD were being married (OR=1.95; 
95%CI:1.33-2.86), divorced (OR=1.26; 95%CI:1.26-3.56) and 
widowed (OR=4.59; 95%CI:2.51-8.37); and for LSD only to 
consume alcohol daily (OR=0.41; 95%CI:0.24-0.70). For the ≥ 
65 years group they were, for SSD, never smoked (OR=0.39; 
Figure 2. Relationship between sleep duration and chronic diseases.
95%CI:0.16-0.96) and the high adherence to the Mediterranean 
diet (OR=0.56; 95%CI:0.36-0.86). For the LSD it was being ac-
tive (OR=0.60; 95%CI:0.39-0.92) (Table 5).
For the < 65 years group the health and health resources 
consumption factors with a predictive value to SSD were the con-
sumption of  drugs for sleep (OR=0.44; 95%CI:0.24-0.80), to be 
obese (OR=1.74; 95%CI:1.30-2.32), to be hypertense (OR=1.80; 
95%CI:1.36-2.39), to have diabetes (OR=2.14; 95%CI:1.41-
3.23), to have hypercholesteremia (OR=1.98; 95%CI:1.52-
2.58), to have a cardiac disease (OR=1.75; 95%CI:1.06-2.88), to 
suffer from a gastrointestinal disease (OR=2.20; 95%CI:1.42-
3.41), depression (OR=2.14; 95%CI:1.48-3.08), multimor-
bidity (OR=2.28; 95%CI:1.75-2.97), worse physical function 
(OR=2.46; 95%CI:1.98-3.05), worse quality of  life (OR=0.30; 
95%CI:0.14-0.38) and the number of  hospitalizations in the 
previous 12 months (OR=1.48; 95%CI:1.04-2.10); for the 
LSD they were to suffer from a rheumatic disease (OR=1.88; 
95%CI:1.06-3.33), depression (OR=2.55; 95%CI:1.16-4.35), 
worse physical function (OR=1.74; 95%CI:1.21-2.50), worse 
quality of  life (OR=0.30; 95%CI:0.15-0.60) and to be hospital-
ized in the previous 12 months (OR=2.19; 95%CI:1.26-3.80).
For the ≥65 years group the health and health resources 
consumption factors with a predictive value to SSD were to 
be hypertense (OR=1.57; 95%CI:1.07-2.31), to suffer from 
cardiac disease (OR=1.54; 95%CI:1.00-2.37), multimorbid-
ity (OR=2.06; 95%CI:1.41-3.02) and worse physical function 
(OR=1.56; 95%CI:1.14-2.12. For the LSD they were to suf-
fer from a cardiac disease, worse physical function (OR=1.50; 
95%CI:1.06-2.11) and quality of  life (OR=0.30; 95%CI:0.17-
0.52) (Table 6).
DISCUSSION
The associations to chronic diseases and abnormal total 
sleep time namely SSD were found for PT. The prevalence for 
SSD in PT is very high, contrary to LSD. In the USA, data from 
the National Health Interview Survey, for the same cut-off  
value (≤5h/day) the prevalence was much lower, 7.8%28, and 
in a sample of  the Brazilian population, the prevalence value 
for reported SSD with a cut-off  value of  ≤6h/day, was 15.8%5. 
The prevalence value for LSD (≥9h/day) in PT is low (5.9%) if  
compared with the USA (8.5%) and even lower than the Brazil-
ian cohort (21.9%)5. The metropolitan area of  Lisbon, the most 
populated urban region of  the all country, with a high 24h/7days 
rhythm, was the region with a higher prevalence value of  NSD 
(75.8%). No explanation for this result was found, as so, future 
studies evaluating sleep duration comparing urban and rural ar-
eas should be performed in PT.
Diabetes and depression presented a significant as-
sociation with SSD and LSD with an increased risk for both 
conditions.  This was also found in the USA [9]diabetes, and 
cardiovascular disease; and although 7-8 h of  sleep seems to 
confer the least health risk, these findings are often based on 
non-representative data. We hypothesize that short sleep (<7 
h in Brazil5, and in a recent revision study6. This is in line with 
the very high prevalence of  both in the country29. PT has the 
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Table 4. Baseline characteristics by categories of  short (≤5 h/day) and long (≥9h/day) sleep duration, having as reference group the normal sleep duration 
(6-8 h/day) for age groups (< 65years and ≥65 years).






















N (%) 717 (19.8) 2704 (74.7) 199 (5.5) 620 (34.1) 989 (54.5) 207 (11.4)
Sex, N (%)
Male 501 (17.1) 1653 (78.4) 129 (4.6) 0.2605 425 (36.5) 639 (52.8) 126 (10.7) 0.9130
Female 216 (14.4) 1051 (81.2) 70 (4.4) 195 (36.2) 350 (53.8) 81 (10.0)
Age, mean ± (SD) 47.6 (12.2) 40.2 (11.7) 41.8 (14.8) <0.0001 73.6 (6.0) 74.2 (6.8) 76.1 (7.9) 0.0014
NUTS II region N(%)
North 225 (15.7) 831 (79.4) 65 (4.9) 0.1755 179 (37.4) 249 (52.7) 55 (9.9) 0.0840
Centre 131 (16.0) 476 (79.4) 35 (4.6) 129 (33.4) 212 (53.2) 56 (13.4)
Lisbon 127 (14.1) 583 (83.0) 28 (3.0) 117 (42.0) 215 (50.9) 25 (7.1)
Alentejo 40 (20.1) 125 (74.4) 12 (4.7) 35 (23.7) 83 (63.0) 16 (13.3)
Algarve 22 (18.7) 68 (72.3) 6 (9.0) 35 (46.9) 41 (49.4) 2 (3.6)
Azores 81 (13.6) 338 (78.6) 40 (7.8) 49 (28.0) 92 (52.1) 36 (19.9)
Madeira 91 (16.9) 283 (79.9) 13 (3.2) 76 (40.3) 97 (8.5) 17 (8.5)
BMI, mean ± (SD) 26.9 (5.1) 25.2 (4.1) 25.5 (5.3) <0.0001 27.1 (3.8) 26.8 (4.3) 27.2 (5.2) 0.0097
Education level, N (%)
> 12 years 115 (10.4) 782 (87.5) 23 (2.1) <0.0001 27 (18.8) 88 (75.9) 7 (5.3) <0.0001
10-12 years 136 (13.3) 730 (81.7) 52 (5.1) 28 (24.9) 71 (64.6) 14 (10.5)
5-9 years 197 (19.4) 629 (76.2) 42 (4.4) 66 (24.5) 138 (68.2) 22 (7.4)
0-4 years 266 (25.9) 558 (66.7) 80 (7.4) 490 (40.7) 686 (48.2) 159 (11.2)
Marital status, N (%)
Single 108 (9.2) 665 (85.7) 46 (5.1) <0.0001 26 (21.2) 48 (66.6) 11 (12.2) 0.5327
Married 460 (19.3) 1643 (76.7) 114 (4.0) 373 (35.3) 624 (54.5) 121 (10.2)
Divorced 63 (20.5) 211 (73.7) 20 (5.8) 23 (47.0) 55 (44.7) 8 (8.4)
Widowed 55 (41.3) 61 (54.7) 8 (4.0) 195 (39.1) 258 (50.1) 64 (10.8)
Consensual union 31 (14.7) 122 (81.3) 11 (4.5) 3 (34.3) 4 (48.6) 1 (17.2)
Employment status, N (%)
Employed full-time/part-
time/ domestic 483 (15.1) 2095 (81.1) 128 (3.9) 0.0198 540 (36.9) 883 (52.9) 183 (10.2) 0.5384
Retired/unemployed/ 
temporary work 233 (17.9) 607 (75.5) 71 (6.7) 78 (31.2) 103 (56.3) 24 (12.5)
Alcohol intake, N (%)
Daily 283 (18.1) 755 (75.9) 81 (6.0) 0.0157 290 (37.1) 387 (51.2) 95 (11.7) 0.7278
Occasionally 179 (17.0) 704 (80.0) 40 (3.0) 192 (36.7) 354 (53.7) 73 (9.6)
Never 253 (13.7) 1240 (81.9) 78 (4.4) 136  (33.9) 247 (9.6) 37 (9.4)
Smoking habits, N (%)
Current smoker 443 (16.9) 1565 (78.9) 104 (4.2) 0.3933 458 (38.0) 707 (51.2) 151 (10.9) 0.2133
Past smoker 141 (15.9) 532 (78.9) 49 (5.2) 135 (35.4) 232 (55.2) 44 (9.5)
Never 132 (13.4) 605 (82.0) 46 (4.5) 25 (22.0) 49 (9.5) 12 (9.3)
Physical activity, N(%)
Inactive 413 (16.3) 1442 (79.6) 113 (4.2) 0.6342 390 (35.0) 593 (52.6) 148 (12.4) 0.1156
Active 304 (15.3) 1262 (79.9) 86 (4.9) 230 (38.5) 396 (54.3) 59 (10.4)
Time watching TV, N (%)
< 5 hours/per day 655 (15.8) 2562 (80.0) 171(4.3) 0.3449 515 (37.4) 804 (52.5) 162 (10.1) 0.5578
≥ 5 hours/per day 60 (16.0) 139 (76.3) 28 (7.7) 103 (32.5) 179 (55.7) 43 (11.8)




highest prevalence of  diabetes when compared with European 
countries29; in our data the crude odds ratio is 3.10 for SSD 
and 2.58 for LSD; these values are lower, but still significant for 
the multivariable adjusted model. In clinical terms these associa-
tions reflect a share of  sleep duration in the risk of  diabetes, 
although other factors such as low physical activity also shown 
in our study, must have significant contributions.
The prevalence of  depression in PT is among the high-
est values in the WHO European Region (5.7%), since only 
Ukraine and Estonia present higher values30 The odds ratio be-
tween depression and SSD is 1.98 and LSD is 2.16 for the crude 
analysis, with values a bit lower but significant for the multivari-
able adjusted model; in our sample the influence of  age, gender, 
region and education in the association between sleep duration 
and depression is minor when compared with diabetes. How-
ever in the sub-sample of  older adults from the EpiDoc cohort, 
the prevalence of  depression is higher in the elder (11.8%)31 
when compared to WHO data30.
Obesity was a predictor for SSD. These  results were in 
accordance with previous studies6,9,32 in a twin study14 and also in 
adolescents33. The mean BMI for Portuguese males and females 
was 26.7kg/m2 and 25.7kg/m2 respectively; the prevalence of  
obesity was in 2014 19.8% for males and 20.3% for females. In 
fact these data are a bit lower when compared with the mean 
EU data29, and therefore this low obesity prevalence may ex-
plain the low odds ratio values found. For LSD, in the adjusted 
model, this association was not found, contrary as observed in 
other studies; LSD was associated with an increased sedentary 
behavior, inactivity, and obesity6,32. Abdominal fat, besides being 
a health risk by itself  for cardiometabolic diseases34, the waist 
circumference was not measured, although the association to 
BMI is well established35.
The adherence to Mediterranean diet was analyzed as 
a proxy of  healthy diet. Although being a protective variable 
to SSD, in the adjusted analysis this association was not found. 
A previous study resulting from an analysis of  the adherence 
to the Mediterranean diet between 1961 and 2003 had already 
showed that the adherence to Mediterranean diet has gradually 
declined in the last years in the Portuguese population36.
In the USA’s, the U-shaped risk was observed for hy-
pertension and cardiovascular disease9. In our study hyperten-
sion had an increased risk only for SSD and cardiovascular 
aAnova and Pearson Qui2 tests
High adherence to MD 
(PREDIMED ≥ 10) 68 (14.0) 327 (82.3) 20 (3.4) 0.4111 54 (25.2) 112 (62.6) 20 (10.4) 0.0372
Low adherence to MD 
(PREDIMED ≤ 10) 649 (16.1) 2377 (79.3) 179 (4.6) 566 (37.7) 877 (52.1) 187 (10.2)
Non-communicable chronic 
diseases (self-reported), N (%)
Hypertension 218 (26.7) 530 (69.1) 50 (4.2) <0.0001 367 (41.7) 523 (48.9) 101 (9.4) 0.0238
Diabetes 75 (32.3) 144 (61.3) 19 (6.4) <0.0001 149 (44.1) 210 (44.6) 47 (11.3) 0.0689
Hypercholesterolemia 245 (26.2) 597 (68.2) 55 (5.6) <0.0001 320 (40.9) 457 (50.0) 86 (9.8) 0.1583
Pulmonary disease 26 (25.0) 65 (70.7) 4 (4.3) 0.0803 39 (38.4) 48 (46.3) 16 (15.3) 0.3096
Cardiac disease 62 (24.0) 155 (69.8) 21 (6.3) 0.0147 156 (40.7) 204 (43.8) 69 (15.6) 0.0097
Gastrointestinal disease 98 (28.7) 164 (66.2) 20 (5.1) 0.0001 92 (42.4) 123 (46.1) 27 (11.5) 0.2634
Neurologic disease 27 (14.5) 98 (79.6) 10 (4.5) 0.7730 27 (30.2) 31 (60.3) 9 (9.6) 0.6007
Allergy 90 (15.9) 310 (80.9) 12 (4.5) 0.6601 45 (35.9) 61 (48.7) 16 (15.3) 0.2834
Neoplasm disease 34 (20.0) 98 (76.4) 7 (3.7) 0.4149 59 (41.9) 83 (44.0) 24 (14.1) 0.2785
Rheumatic disease 89 (18.8) 204 (73.3) 24 (8.0) 0.0191 65 (41.2) 92 (49.6) 19 (9.2) 0.6672
Depression 89 (30.0) 181 (61.6) 20 (4.5) <0.0001 52 (34.6) 84 (53.3) 17 (12.1) 0.7781
Anxiety 51 (25.0) 113 (68.7) 9 (6.4) 0.0477 28 (30.5) 46 (55.0) 14 (14.5) 0.4362
Multimorbidity,  N (%)
Yes 281 (26.9) 696 (67.9) 65 (5.2) <0.0001 369 (43.3) 534 (47.4) 107 (9.3) 0.0003
No 367 (12.4) 1878 (83.6) 115 (4.1) 175 (28.2) 314 (63.2) 51 (8.6)
Hospitalized in previous 12 
months N(%) 89 (20.9) 266 (70.1) 26 (8.4) 0.0007 123 (40.1) 159 (47.4) 44 (10.4) 0.1925
Physical function, mean ± (SD)
HAQ score (0-3) 0.4 (0.7) 0.2 (0.4) 0.3 (0.6) <0.0001 0.8 (0.7) 0.6 (0.7) 0.8 (0.7) <0.0001
Quality of  life, mean ± 
(SD)
EQ-5D-3L score 0.6 (0.3) 0.9 (0.2) 0.8 (0.3) <0.0001 0.6 (0.3) 0.7 (0.3) 0.5 (0.3) <0.0001
Drugs for sleep (self- reported), 
N(%)
Yes 35 (36.2) 48 (59.4) 4 (4.4) 0.0002 58 (43.8) 74 (47.7) 15 (8.5) 0.2720 
No 682 (15.4) 2656 (80.1) 195 (4.5) 562 (35.9) 915 (53.6) 192 (10.5)
Continuation Table 4.
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Table 5. Lifestyles factors associated with short and long sleep durations for age groups (< 65 and ≥ 65 years).
<65 years ≥65 years
Crude Multivariable adjusteda Crude Multivariable adjusteda
Sleep duration 























OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Alcohol intake
Daily 0.89 0.65-1.23 0.47 0.29-0.77 0.97 0.69-1.38 0.41 0.24-0.70 0.94 0.60-1.49 0.78 0.50-1.21 0.99 0.61-1.60 0.89 0.53-1.49
Occasionally 0.70 0.51-0.97 0.68 0.43-1.08 0.83 0.61-1.13 0.74 0.48-1.45 0.82 0.56-1.21 0.72 0.42-1.22 1.06 0.70-1.58 0.77 0.44-1.34
Smoking habits
Past smoker 0.94 0.69-1.28 1.24 0.79-1.95 0.91 0.69-1.37 1.36 0.81-2.27 0.86 0.54-1.38 0.81 0.52-1.25 0.92 0.54-1.55 0.91 0.52-1.59
Never 0.76 0.55-1.06 1.08 0.65-1.81 0.83 0.57-1.20 1.19 0.70-2.04 0.41 0.20-0.91 0.64 0.25-1.61 0.39 0.16-0.96 0.56 0.19-1.64
Physical activity
Active 0.93 0.72-1.21 1.17 0.78-1.72 1.07 0.82-1.39 1.33 0.90-1.96 1.07 0.71-1.61 0.57 0.38-0.85 1.17 0.78-1.73 0.60 0.39-0.92
Time watching TV
≥5 hours/per day 1.06 0.52-2.20 1.89 0.84-4.26 0.87 0.47-1.62 1.63 0.78-3.42 0.82 0.48-1.40 1.10 0.68-1.79 0.74 0.46-1.21 1.06 0.63-1.78
Marital status
Married 2.36 1.60-3.51 0.87 0.55-1.35 1.95 1.33-2.86 0.66 0.41-1.05 2.04 0.89-4.67 1.02 0.39-2.69 2.01 0.78-5.22 1.02 0.37-2.85
Divorced 2.60 1.54-4.41 1.32 0.67-2.58 2.12 1.26-3.56 0.91 0.46-1.80 3.31 0.85-12.96 1.02 0.30-3.51 3.52 0.97-12.77 1.21 0.32-4.52
Widowed 7.06 3.89-12.82 1.24 0.42-3.62 4.59 2.51-8.37 0.62 0.21-1.84 2.46 1.06-5.67 1.17 0.43-3.23 2.13 0.80-5.62 1.08 0.37-3.13





0.84 0.56-1.24 0.71 0.39-1.31 0.88 0.57-1.34 0.69 0.36-1.31 0.56 0.36-0.86 1.00 0.51-1.93 0.65 0.43-0.99 1.07 0.56-2.05
aOdds ratios from logistic regression model adjusted for sex, NUTS II regions and educational level.
disease only for LSD. The prevalence of  high blood pressure 
in PT is high (28.1%) in 2014, and it is the 9th highest preva-
lence in Europe29, the highest values include Russian Federa-
tion, other countries from the Eastern Europe and Luxem-
bourg. The odds ratio for SSD is high (2.86) but decreases, 
although remaining significant in the multivariable adjusted 
model (1.43); these results suggest that sleep reduction is in-
cluded in a set of  other risk factors for hypertension. The age 
standardized prevalence for 100,000 inhabitants of  cardio-
vascular disease in PT in 2015 is 4,765 for females and 5,764 
for males, which, within the European framework, are among 
the lowest values29. This might be a partial explanation for the 
absent association with SSD, which has been found by other 
authors in the USA37 and Netherlands38. In fact this result de-
serves further studies since the prevalence of  cardiovascular 
disease is similar in Netherlands and PT. For the association 
only to LSD to cardiovascular disease no explanation can be 
found since like stated by Covassin & Singh39, experimental 
evidence corroborating harmful cardiovascular effects of  ex-
cessive sleep duration is lacking, which contributes to making 
any causal association between long sleep and cardiovascular 
disease more elusive. Hypercholesterolemia had an increased 
risk for SSD in accordance to literature which indicates SSD 
as a risk factor for metabolic function40,41 PT has a reasonable 
prevalence of  raised blood cholesterol (16.7), which is much 
lower than in most Northern and Eastern EU countries29 and 
USA42. The Mediterranean diet might be an explanation in 
spite of  the reduced adherence. Contrary to a previous study5 
rheumatic diseases were not associated with sleep duration. 
Most of  the rheumatic diseases are inflammatory diseases so, 
an association namely to SSD was expected43. The same hap-
pened to cancer, in this population an association with sleep 
duration was not found. The association to sleep duration and 
cancer, namely for LSD, was described in studies for cancer 
related mortality44,45. In this study, there was an increased risk 
for neoplasm disorders in SSD and LSD, although, adjusting 
for age, gender, regions and educational level this association 
was not found; the low prevalence of  LSD may be a possible 
explanation, as well as the low rates of  cancer for PT compar-
ing to other countries15. The reduced immunological defenses 
in individuals with short or increased sleep durations was dem-
onstrated by Patel et al.46 in a study where pneumonia risk was 
higher for these individuals; in our study pulmonary disease, 
had an association in the univariate analysis, which was missed 
in the adjusted data. An association with SSD was however 
expected since the chronic obstructive pulmonary disease is 
usually one of  the most prevalent pulmonary diseases and is 
associated to SSD47,48. Even separating by age groups below 
and above 65 years this association was still not found.
Anxiety is usually associated to insomnia; nevertheless in 
this population the association to SSD was not found, only in 
the group <65 years this association was present49.
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Table 6. Health and health resources consumption factors associated with short and long sleep durations for age groups (<65 and ≥65 years).
<65 years ≥65 years
Crude Multivariable adjusteda Crude Multivariable adjusteda
Sleep duration 























OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI
Drugs for sleep 
(self- reported)








Hypertension 2.27 1.73-3.00 1.11 0.72-1.69 1.80 1.36-2.39 0.90 0.59-1.37 1.63 1.08-2.44 1.07 0.71-1.61 1.57 1.07-2.31 1.10 0.72-1.69
Diabetes 2.83 2.91-4.20 1.96 1.07-3.58 2.14 1.41-3.23 1.54 0.85-2.78 1.63 0.99-2.66 1.47 0.94-2.28 1.52 0.99-2.32 1.44 0.92-2.24
Hypercholesterolemia 2.34 1.80-3.04 1.61 1.07-2.44 1.98 1.52-2.58 1.41 0.95-2.10 1.38 0.92-2.06 0.98 0.65-1.47 1.37 0.95-1.99 0.92 0.60-1.40
Pulmonary disease 1.81 1.05-3.13 1.11 0.38-3.25 1.36 0.80-2.29 0.86 0.29-2.54 1.22 0.69-2.17 1.76 0.89-3.50 1.26 0.70-2.27 1.56 0.73-3.31
Cardiac disease 1.81 1.11-2.94 1.66 0.92-1.99 1.75 1.06-2.88 1.63 0.94-2.83 1.49 0.95-2.35 2.32 1.56-3.46 1.54 1.00-2.37 2.18 1.43-3.30
Gastrointestinal 
disease 2.38 1.52-3.70 1.44 0.73-2.83 2.20 1.42-3.41 1.55 0.80-3.02 1.43 0.89-2.29 1.35 0.73-2.50 1.59 0.99-2.55 1.43 0.75-2.72
Neurologic disease 0.91 0.51-1.65 1.35 0.50-3.63 0.86 0.47-1.56 1.30 0.52-3.27 0.73 0.37-1.43 0.82 0.32-2.12 0.65 0.31-1.40 0.74 0.28-1.98
Allergy 1.00 0.66-1.50 0.68 0.29-1.60 1.10 0.73-1.67 0.77 0.30-1.96 1.08 0.66-1.79 1.71 0.87-3.35 1.11 0.67-1.84 1.60 0.78-3.25
Neoplastic disease 1.34 0.82-2.19 0.85 0.34-2.14 1.13 0.68-1.89 0.76 0.30-1.91 1.44 0.72-2.90 1.77 0.99-3.14 1.49 0.75-2.97 1.69 0.90-3.17
Rheumatic disease 1.31 0.91-1.90 2.05 1.17-3.61 1.15 0.80-1.65 1.88 1.06-3.33 1.25 0.61-2.50 0.95 0.51-1.77 1.18 0.65-2.14 0.88 0.47-1.64
Depression 2.67 1.85-3.86 2.62 1.40-4.90 2.14 1.48-3.08 2.25 1.16-4.35 0.94 0.58-1.54 1.22 0.63-2.36 1.03 0.64-1.66 1.34 0.68-2.64
Anxiety 1.91 1.24-2.94 1.71 0.57-5.14 1.70 1.09-2.66 1.58 0.49-5.10 0.80 0.44-1.45 1.42 0.61-3.27 0.75 0.41-1.37 1.31 0.54-3.19
Multimorbidity
Yes 2.68 2.06-4.47 1.58 1.02-2.45 2.28 1.75-2.97 1.42 0.88-2.29 2.05 1.40-3.00 1.44 0.88-2.35 2.06 1.41-3.02 1.39 0.83-2.34
Physical function
HAQ score 2.97 2.43-3.64 2.12 1.50-3.00 2.46 1.98-3.05 1.74 1.21-2.50 1.63 1.21-2.21 1.56 1.16-2.10 1.56 1.14-2.12 1.50 1.06-2.11
Quality of  life
EQ-5D-3L score 0.17 0.11-0.26 0.24 0.12-0.47 0.23 0.14-0.38 0.30 0.15-0.60 0.70 0.40-1.23 0.26 0.16-0.43 0.77 0.44-1.33 0.30 0.17-0.52
Hospitalised in 
previous 12 months 1.56 1.11-2.20 2.34 1.36-4.04 1.48 1.04-2.10 2.19 1.26-3.80 1.29 0.89-1.89 1.45 0.93-2.27 1.41 0.98-2.03 1.49 0.94-2.35
aOdds ratios from logistic regression model adjusted for sex, NUTS II regions and educational level.
An increased risk of  multimorbidity for people report-
ing SSD was also found in our study like in a Brazilian cohort, 
where it was stated that people suffering from chronic diseases 
have a greater chance of  exhibiting a SSD pattern, and that such 
individuals may have a tendency towards an accumulation of  
sleep problems, generating a deficiency in the normal sleep pat-
tern5. In Figure 2 it was possible to observe the U shape for 
the relationship between sleep duration and number of  comor-
bidities. Like in other study where 7h of  sleep presented a lower 
mortality risk13 also in our study 7h of  sleep presented the lower 
number of  comorbidities, increasing with higher or lower sleep 
time.
Poor quality of  life and poor physical functioning pre-
sented an increased risk for both conditions SSD and LSD. This 
was also well demonstrated in a representative sample from the 
USA population50. Worse quality of  life and health complaints 
were also reported for sleep deprivation in Portuguese adoles-
cents33.
The number of  hospitalizations represents costs to the 
National Health Care System and in this study almost 30% of  
the total sample, had abnormal sleep (SSD or LSD) and report-
ed to be hospitalized in the previous 12 months.
A recent study in the UK presented the economics costs 
of  insufficient sleep across five different OECD countries: up 
to $680 billion are lost each year across these countries due to 
insufficient sleep. Insufficient sleep increases mortality risk, and 
the amounts of  working time lost due to absenteeism or presen-
teeism7. All the countries evaluated in this study presented lower 
prevalence values for SSD than PT, demonstrating that this 
might be a very important issue for the Portuguese economy.
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One of  the major strengths of  our study is its large 
sample size and representativeness with mainland and islands. 
The other is the fact that in the EpiDoc1 participants had a 
complete clinical examination performed by a physician and 
besides EpiDoc3 being a telephonic interview, the registries to 
confirm chronic diseases were consulted. Our study had also 
some limitations: since this is a cross-sectional study it was not 
possible to establish the temporal nature of  the association 
between the tested variables and self-reported sleep duration; 
daily sleep duration was measured subjectively by self-report, 
an objective measure like actigraphy would be of  great value, 
giving the possibility of  register workdays and off-days; ask-
ing for workdays and off-days separately would be something 
very important since a recent study51 showed that when asking 
about total sleep time duration, the answer reflects only work-
days times. Sleep timing and sleep quality were also variables not 
considered in this study and are important factors when study-
ing sleep. The influence of  menopause was not evaluated in this 
study and there are clear evidences that menopause by itself  
influences objective sleep patterns52.
Like in the majority of  questionnaires there were some 
questions that the volunteers did not know or refused to answer, 
resulting in some missing values. However, it was not possible to 
eliminate those participants because the representativeness for 
the Portugal could be compromised.
This study screens the self-reported daily sleep duration 
for the Portuguese population and shows the very high preva-
lence of  self-reported SSD in the population. Also, the increased 
risk for chronic diseases and the high costs for the Portuguese 
National Health Care System were well demonstrated, with the 
association between SSD and LSD with chronic diseases and 
with a higher number of  hospitalizations. Although some of  the 
chronic diseases that are commonly associated to SSD and LSD 
like rheumatic diseases and cancer were not significantly associ-
ated in this population. Looking closer to the population bellow 
65 years of  age some significant differences were found. Being 
unemployed before retirement is associated to SSD as well as 
being divorced and widowed, these are stress factors that can 
steal sleep. For some chronic diseases the association to SSD or 
LSD is only present in individuals bellow 65 years of  age. The 
significant association to sleep duration and increased mortal-
ity risk only for this age group and not in older individuals was 
shown in a Swedish cohort13, the same relationship might be 
present in our sample. In a future follow up of  this cohort, this 
relationship should be tested for Portugal.
Future studies are needed evaluating not only reported 
daily total sleep time, but also the time of  the day that people 
sleep, preferably with objective quantitative measures. Studies 
on interventions aimed at sleep duration should be conducted 
to investigate whether adverse health risks decrease in different 
community settings.
This study emphasizes the burden of  self-reported SSD for 
PT, its consequences to health and the need to increase sleep aware-
ness campaigns enhancing the importance of  sleep in health.
Furthermore, it emphasizes that chronic diseases risks 
are dependent on multiple parameters which varying in different 
countries or regions, imply the need of  regional studies taking 
into account the local specificities.
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